These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 34610580)

  • 21. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Clinical experience of the use of agomelatine in the treatment of patients with depression and chronic brain ischemia].
    Antonen EG; Nikitina MV; Kruchek MM
    Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(12):79-85. PubMed ID: 26978498
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients.
    De Wilde J; Spiers R; Mertens C; Bartholomé F; Schotte G; Leyman S
    Acta Psychiatr Scand; 1993 Feb; 87(2):141-5. PubMed ID: 8447241
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acute efficacy of fluoxetine versus sertraline and paroxetine in major depressive disorder including effects of baseline insomnia.
    Fava M; Hoog SL; Judge RA; Kopp JB; Nilsson ME; Gonzales JS
    J Clin Psychopharmacol; 2002 Apr; 22(2):137-47. PubMed ID: 11910258
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chronic agomelatine and fluoxetine induce antidepressant-like effects in H/Rouen mice, a genetic mouse model of depression.
    El Yacoubi M; Dubois M; Gabriel C; Mocaër E; Vaugeois JM
    Pharmacol Biochem Behav; 2011 Dec; 100(2):284-8. PubMed ID: 21843546
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and tolerability of Paroxetine 20 mg daily in the treatment of depression and depression associated anxiety.
    Chaudhry HR; Qureshi Z; Tareen IA; Yazdani I
    J Pak Med Assoc; 2002 Nov; 52(11):518-25. PubMed ID: 12585372
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Paroxetine in the treatment of depression in geriatric patients--a double-blind comparative study with fluoxetine].
    Schöne W; Ludwig M
    Fortschr Neurol Psychiatr; 1994 Sep; 62 Suppl 1():16-8. PubMed ID: 7959520
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial.
    Stahl SM; Fava M; Trivedi MH; Caputo A; Shah A; Post A
    J Clin Psychiatry; 2010 May; 71(5):616-26. PubMed ID: 20361916
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of the novel antidepressant agomelatine for anxiety symptoms in major depression.
    Stein DJ; Picarel-Blanchot F; Kennedy SH
    Hum Psychopharmacol; 2013 Mar; 28(2):151-9. PubMed ID: 23532747
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline.
    Kasper S; Hajak G; Wulff K; Hoogendijk WJ; Montejo AL; Smeraldi E; Rybakowski JK; Quera-Salva MA; Wirz-Justice AM; Picarel-Blanchot F; Baylé FJ
    J Clin Psychiatry; 2010 Feb; 71(2):109-20. PubMed ID: 20193645
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine.
    Greist J; McNamara RK; Mallinckrodt CH; Rayamajhi JN; Raskin J
    Clin Ther; 2004 Sep; 26(9):1446-55. PubMed ID: 15531007
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of agomelatine treatment on C-reactive protein levels in patients with major depressive disorder: an exploratory study in "real-world," everyday clinical practice.
    De Berardis D; Fornaro M; Orsolini L; Iasevoli F; Tomasetti C; de Bartolomeis A; Serroni N; De Lauretis I; Girinelli G; Mazza M; Valchera A; Carano A; Vellante F; Matarazzo I; Perna G; Martinotti G; Di Giannantonio M
    CNS Spectr; 2017 Aug; 22(4):342-347. PubMed ID: 27702411
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR.
    Kennedy SH; Rizvi S; Fulton K; Rasmussen J
    J Clin Psychopharmacol; 2008 Jun; 28(3):329-33. PubMed ID: 18480691
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A double-blind, randomized, fluoxetine-controlled, multicenter study of paroxetine in the treatment of depression.
    Tignol J
    J Clin Psychopharmacol; 1993 Dec; 13(6 Suppl 2):18S-22S. PubMed ID: 8106650
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A double-blind study of paroxetine compared with fluoxetine in geriatric patients with major depression.
    Schöne W; Ludwig M
    J Clin Psychopharmacol; 1993 Dec; 13(6 Suppl 2):34S-39S. PubMed ID: 8106654
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study.
    Stein DJ; Ahokas AA; de Bodinat C
    J Clin Psychopharmacol; 2008 Oct; 28(5):561-6. PubMed ID: 18794654
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical efficacy of agomelatine in depression: the evidence.
    den Boer JA; Bosker FJ; Meesters Y
    Int Clin Psychopharmacol; 2006 Feb; 21 Suppl 1():S21-4. PubMed ID: 16436936
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A double-blind study of paroxetine, fluoxetine, and placebo in outpatients with major depression.
    Fava M; Amsterdam JD; Deltito JA; Salzman C; Schwaller M; Dunner DL
    Ann Clin Psychiatry; 1998 Dec; 10(4):145-50. PubMed ID: 9988054
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Early effect on general interest, and short-term antidepressant efficacy and safety of agomelatine (25-50mg/day) and escitalopram (10-20mg/day) in outpatients with Major Depressive Disorder. A 12-week randomised double-blind comparative study.
    Udristoiu T; Dehelean P; Nuss P; Raba V; Picarel-Blanchot F; de Bodinat C
    J Affect Disord; 2016 Jul; 199():6-12. PubMed ID: 27054610
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial.
    Lustman PJ; Freedland KE; Griffith LS; Clouse RE
    Diabetes Care; 2000 May; 23(5):618-23. PubMed ID: 10834419
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.